{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=49",
    "query": {
      "condition": "Healthy Volunteers.",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 7030,
    "total_pages": 703,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:29:46.847Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05436912",
      "title": "A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2018-12-10",
      "completion_date": "2019-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 7,
      "location_summary": "Anaheim, California • Monterey Park, California • Tustin, California + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Monterey Park",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05436912"
    },
    {
      "nct_id": "NCT07008664",
      "title": "Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer",
        "Lung Cancer Screening",
        "Healthy Volunteers (HV)",
        "Unhealthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Epigenetic Signature Assay",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "2025-03-31",
      "completion_date": "2032-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Glen Burnie, Maryland",
      "locations": [
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07008664"
    },
    {
      "nct_id": "NCT05781399",
      "title": "First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Phenylketonuria"
      ],
      "interventions": [
        {
          "name": "JNT-517 Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo Suspension",
          "type": "DRUG"
        },
        {
          "name": "JNT-517 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 163,
      "start_date": "2022-10-31",
      "completion_date": "2025-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05781399"
    },
    {
      "nct_id": "NCT03974399",
      "title": "BDNF Levels After Bacopa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Memory"
      ],
      "interventions": [
        {
          "name": "Bacopa Monnieri",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Roskamp Institute Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "60 Years to 78 Years"
      },
      "enrollment_count": 44,
      "start_date": "2019-05-30",
      "completion_date": "2020-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-02",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Sarasota, Florida",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03974399"
    },
    {
      "nct_id": "NCT03630601",
      "title": "Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Healthy Subject",
        "Malignant Soft Tissue Neoplasm",
        "Sarcoma",
        "Skin Carcinoma"
      ],
      "interventions": [
        {
          "name": "Photoacoustic Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2018-06-28",
      "completion_date": "2023-03-15",
      "has_results": false,
      "last_update_posted_date": "2023-03-31",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630601"
    },
    {
      "nct_id": "NCT00599001",
      "title": "Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "SD-101",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2008-01",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00599001"
    },
    {
      "nct_id": "NCT00650312",
      "title": "Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Metformin Hydrochloride ER Tablets 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Glucophage® XR Tablets 500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2002-10",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00650312"
    },
    {
      "nct_id": "NCT06175312",
      "title": "Probing the Role of Feature Dimension Maps in Visual Cognition: Impact of Salience Level (Expt 1.1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Basic Science: Visual Attention in Healthy Participants",
        "Basic Science: Neural Representations of Location",
        "Attention"
      ],
      "interventions": [
        {
          "name": "Stimulus properties: salience-defining feature",
          "type": "OTHER"
        },
        {
          "name": "Stimulus properties: magnitude of salience",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Santa Barbara",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-04-25",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Santa Barbara, California",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06175312"
    },
    {
      "nct_id": "NCT03932864",
      "title": "Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "MGTA-145",
          "type": "BIOLOGICAL"
        },
        {
          "name": "plerixafor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ensoma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 107,
      "start_date": "2019-04-22",
      "completion_date": "2020-02-25",
      "has_results": false,
      "last_update_posted_date": "2024-01-11",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03932864"
    },
    {
      "nct_id": "NCT02353299",
      "title": "Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Silenor 6 mg",
          "type": "DRUG"
        },
        {
          "name": "zolpidem 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Currax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "21 Years to 50 Years · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2015-01",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-01-02",
      "last_synced_at": "2026-11-19T06:29:46.847Z",
      "location_count": 1,
      "location_summary": "Novi, Michigan",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02353299"
    }
  ]
}